PDF Cover

Stereotactic Surgery Systems Market

The market for Stereotactic Surgery Systems was estimated at $27.4 billion in 2025; it is anticipated to increase to $33.5 billion by 2030, with projections indicating growth to around $41.0 billion by 2035.

Report ID:DS1801128
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Stereotactic Surgery Systems
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Stereotactic Surgery Systems Market Outlook

Revenue, 2025

$27.4B

Forecast, 2035

$41.0B

CAGR, 2026 - 2035

4.1%

The Stereotactic Surgery Systems industry revenue is expected to be around $27.4 billion in 2026 and expected to showcase growth with 4.1% CAGR between 2026 and 2035. With rising interest in precision and safety in the operating theatre, Stereotactic Surgery Systems are becoming increasingly crucial in the field of neuro oncology and the treatment of complex cranial and functional disorders. Increasing demand is driven by the growing incidence of brain tumours, the increasing number of people undergoing neurodegenerative disorders surgery and epilepsy surgery, and the shift towards stereotactic radiosurgery which results in fewer patients requiring hospital stays and complications. Advances in stereotactic navigation, robotic assisted surgical instruments and three dimensional imaging are providing more accurate treatments and streamlining the process, which highlights the part that such technologies play in neurosurgery and cancer treatment.

Modern Stereotactic Radiosurgery Systems include sophisticated hardware, as well as software, which together employ X ray imaging, 3D imaging, and a treatment machine, to enable precise targeting and deliver the radiation dose directly to the tumour site. Its key features include the ability to provide accurate positioning to within one millimetre, sophisticated software to help doctors in the treatment of brain tumours, the merging of images in real time and also integration with treatment planning systems for radiotherapy and for surgery. Applications in brain tumours and functional neurosurgery together represent the greatest share of the market at 78.9%, which reflects the very dominant use of gamma knife radiosurgery in treating brain metastases, Parkinsons disease, epilepsy, tremors and pain. The market for Stereotactic Surgery Systems, also known as Stereotactic Radiosurgery,, led by LINAC based Stereotactic Surgery Systems, will generate $10.17 billion in revenue by the year 2025. This growth is largely driven by the expansion of outpatient Stereotactic Radiosurgery, as well as increasing reimbursement for stereotactic surgery and the growing infrastructure for image guided neurosurgery in both developed and developing countries.

Stereotactic Surgery Systems market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Stereotactic Surgery Systems Market Outlook

Market Key Insights

  • The Stereotactic Surgery Systems market is projected to grow from $27.4 billion in 2025 to $41.0 billion in 2035. This represents a CAGR of 4.1%, reflecting rising demand across Radiosurgery, Biopsy, and Functional Neurosurgery.

  • Companies of the standing of Accuray Inc., Medtronic plc and Siemens Healthineers are the market leaders that are influencing this markets competitive dynamics.

  • The U.S. and Germany together represent the top two markets for stereotactic surgery systems, projected to exhibit compound annual growth rates of 2.9 and 3.8% respectively from 2025 to 2030.

  • Markets in developing countries such as the Philippines, South Africa and Brazil are forecast to experience the highest growth rate with compound annual growth rates ranging between 4.5% and 5.7%.

  • The adoption of minimally invasive techniques in the stereotactic neurosurgery field will significantly alter the value chain in the US and German markets. This development is forecast to increase the value of the market for stereotactic surgery systems by $682 million by 2030.

  • The Stereotactic Surgery Systems market is forecast to grow by $13.6 billion from 2025 to 2035, with the AVM and functional neurosurgery applications market represented by manufacturers expected to increase significantly.

  • With

    increasing prevalence of neurological disorders paired with surge in demand for minimally invasive precision surgery, and

    Technological Innovation in AI, Robotics, and Real‑Time Imaging Enhancing Surgical Precision, Stereotactic Surgery Systems market to expand 49% between 2025 and 2035.

stereotactic surgery systems market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Stereotactic Surgery Systems - Country Share Analysis

Opportunities in the Stereotactic Surgery Systems

Across the second tier Indian hospitals, an untapped market exists for stereotactic radiosurgery systems to provide radiotherapy. With the growth of the public and private oncology and insurance networks which offer affordable insurance, linac based radiotherapy platforms that provide image guided radiotherapy and stereotactic radiosurgery are also currently in line with this trend. Worldwide, linear accelerator based systems will rise from a value of $10.17 billion in the year 2025 to $12.49 billion in 2030, at a compound annual growth rate of 4.2%. However, adoption within India could be greater than this. Healthcare companies offering flexible service plans, education and financing solutions can satisfy a strong demand for cancer treatment.

Growth Opportunities in North America and Asia-Pacific

The Stereotactic Surgery Systems market is particularly strong in North America, where brain tumour treatments are the main application region. High volumes of procedures here, are underpinned by neurosurgical navigation systems and image guided surgery platforms of the highest sophistication. Key region's for growth include ageing stereotactic radiosurgery systems being replaced by integrated, software driven technology platforms which integrate Brain Tumours, AVM and Functional Neurosurgery procedures into one system. Another region is the expansion of their operations into networked oncology centres. As the healthcare industry becomes increasingly competitive, medical equipment companies and software firms are striving to stand out in the field by improving their products in region's such as clinical decision making, imaging equipment and financing options. The region has key drivers of growth in the neurosurgery market which include the reimbursement of complex neurosurgery operations, the neuro oncology services, the need for less invasive brain tumour treatments, and the increasing adoption of robot assisted neurosurgery and precision radiotherapy in neurosurgery departments.
Asia Pacific stereotactic surgery system sales are increasingly influenced by two factors: the demand for brain tumour treatment in big cities and a growing requirement for functional neurosurgery in clinics specialising in epilepsy and other movement disorders. In neurosurgery, there are significant opportunities with the use of cost efficient systems which integrate frameless stereotaxy and software that can be adapted, allowing neurosurgeons to begin with the treatment of brain tumours and move on to more complex procedures such as AVMs and functional neurosurgery as their expertise and confidence grow. In this market environment, competition is now between regional suppliers who are willing to undercut prices and the larger multinationals, who compete on factors such as the support they can offer to customers and the training they provide to the medical profession. Key factors influencing the regional CNS market include growing demand for CNS treatments, public sector investment in tertiary care and modernising hospital infrastructure, a shift by patients towards minimally invasive neurosurgery and private hospitals developing their CNS services.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Neurological Disorders Paired with Surge in Demand for Minimally Invasive Precision Surgery

The rising incidence of neurological conditions such as brain tumors, Parkinson’s disease, epilepsy, and movement disorders is also a significant growth driver for the stereotactic surgery systems market. As global populations age, healthcare providers increasingly turn to stereotactic systems for precise targeting and tailored interventions, which improve surgical outcomes and quality of life for complex cases. This trend dovetails with a strong shift toward minimally invasive surgeries, as clinicians and patients favor procedures that reduce operative trauma devices, shorten recovery times, and lower complication risks.
Advancements in AI‑enabled navigation, robotic assistance, and real‑time multimodal imaging are also transforming stereotactic surgery systems by increasing accuracy, reducing operator dependency, and expanding clinical applications. Integration of artificial intelligence and machine learning into planning and intraoperative guidance enhances precision and workflow efficiency. Robotic support and improved imaging modalities like MRI and CT enable surgeons to precisely localize targets and minimize damage to surrounding tissues, driving broader adoption of stereotactic technologies in advanced neurosurgical and oncology centers
02

Restraint: High Equipment Costs and Limited Adoption by Healthcare Facilities

The high capital expense associated with acquiring and maintaining stereotactic surgery systems significantly restrains market growth. Advanced platforms, such as robotic navigation suites and integrated imaging units, can require multimillion‑dollar investments, which many small hospitals and emerging‑market facilities cannot justify. These barriers reduce overall demand, slow installations in rural or budget‑constrained regions, and constrain revenue expansion as institutions delay or forego purchases despite clinical benefits.
03

Opportunity: Growing demand for Gamma Knife Stereotactic Surgery Systems in North American functional neurosurgery and oncology centers and Untapped CyberKnife-based Stereotactic Surgery Systems potential in Asia-Pacific outpatient spine and lung radiosurgery clinics

Growing demand in North America for the Gamma Knife Stereotactic Radisurgery Instrument is due to the increasing incidence of complex brain disorders and brain metastases, and neurological movement disorders. In the fields of neuro oncology and functional neurosurgery, the demand is growing for treatment machines capable of pinpoint accuracy of less than one millimetre, sophisticated treatment planning and the integration of all forms of imaging. The worldwide market for Gamma Knife radiosurgery systems is forecast to rise from $8.93 billion in 2025 to $10.46 billion by the year 2030; a compound annual growth rate of 3.2%. In hospitals with a cancer centre and those which are academic tertiary, systems that include clinical information systems, treatment planning software and outcome tracking will experience the fastest growth.
There are opportunities in the Asia Pacific region for CyberKnife radiosurgery systems which perform stereotactic surgery for spine and lung patients on an outpatient basis. A rapidly ageing population coupled with limited neurosurgical resources is driving the interest in stereotactic surgery and less invasive neurosurgical procedures. Over the next five years, the market for CyberKnife systems is predicted to increase from $6.25 billion to $8.16 billion. The 5.5% compound annual growth rate of this industry is the highest among all thes. Companies that can tailor lower cost equipment configurations, remote planning support and leasing options to meet customer needs can quickly expand their customer base in cities which are growing rapidly.
04

Challenge: Shortage of Skilled Operators and Training Constraints

A persistent shortage of trained neurosurgeons and technical staff capable of operating complex stereotactic systems limits broader adoption and effective utilization. The steep learning curve and need for specialized education restrict deployment in many regions, particularly outside major urban centers. This workforce gap leads to underutilization of installed systems, delays in procedure throughput, and limits market growth because facilities struggle to justify investment without assured operational expertise.

Supply Chain Landscape

1

Imaging Components

Siemens HealthineersElekta
2

Stereotactic Surgery Systems

Medtronic plcBrainlab AG
3

Software & Services

Accuray Inc.Monteris Medical
4

Clinical End Users

HospitalsNeurosurgery CentersCancer Treatment Centers
Stereotactic Surgery Systems - Supply Chain

Use Cases of Stereotactic Surgery Systems in Radiosurgery & Biopsy

Radiosurgery : Stereotactic Surgery Systems play a role in performing radiosurgery—an advanced technique that delivers targeted radiation therapy to address brain tumors and other anomalies with great precision and minimal invasiveness. The specialized nature of surgery enables its widespread use for its exceptional accuracy. Cutting edge stereotactic radiosurgery systems, like the CyberKnife and Gamma Knife are commonly employed for this purpose. These systems harness advanced technology to deliver radiation to the intended site while safeguardin ity of nearby healthy tissues. Prominent companies in the industry such, as Elekaa nd Accuray have established product offerings tailored to this specific use case. This has significantly boosted their appeal in the market competition.
Biopsy : In biopsy procedures, stereotactic surgery systems are widely used to perform precise, minimally invasive tissue sampling, especially in deep seated brain lesions where traditional surgery is risky. These systems employ advanced 3D coordinate navigation and imaging like CT and MRI to guide biopsy needles with high accuracy in neurological and oncology settings, improving diagnostic confidence and patient outcomes. Leading players such as Medtronic, Brainlab, Elekta, Accuray, and Renishaw dominate this segment with robust image‑guided platforms and strong clinical support networks.
Functional Neurosurgery : In functional neurosurgery, stereotactic surgery systems enable targeted interventions for movement disorders, pain syndromes, and deep brain stimulation by providing real‑time navigation and precise electrode placement. Neurosurgeons in hospitals and specialty centers rely on systems like Medtronic’s StealthStation, Brainlab navigation tools, and Renishaw’s robotic platforms to enhance surgical accuracy and reduce risks. These systems improve outcomes in Parkinson’s disease, essential tremor, and other functional disorders through superior imaging, planning software, and surgical ergonomics.

Recent Developments

Recent strategic developments in the Stereotactic Radiosurgery market show a strong shift toward precision‑guided, robotic‑assisted surgery and AI‑enabled image guidance to enhance clinical outcomes and workflow efficiency. Key players like Medtronic, Elekta, Brainlab, Accuray, and Renishaw are launching advanced navigation platforms and integrating real‑time imaging fusion to improve accuracy in biopsy, radiosurgery, and deep brain procedures. A prominent trend is the adoption of frameless, minimally invasive systems with AI planning and robotic positioning to reduce operative time and broaden neurosurgery and oncology applications.

October 2025 : Monteris Medical entered a strategic partnership with Symphony Robotics to develop an AI‑driven micro‑robotic platform for brain laser ablation and MRI‑guided neurosurgery, aiming to enhance precision for complex tumor and minimally invasive procedures.
September 2025 : Brainlab received FDA 510(k) clearance and launched its Spine Mixed Reality Navigation system in the U.S., combining advanced navigation with mixed‑reality visualization to support precise pedicle screw placement in spinal and stereotactic procedures.
February 2025 : Medtronic earned U.S. FDA approval for its adaptive Deep Brain Stimulation (DBS) system featuring BrainSense™ technology, enhancing real‑time neural signal tracking and personalized therapy for Parkinson’s patients, marking a significant regulatory milestone in neurosurgical stimulation systems.

Impact of Industry Transitions on the Stereotactic Surgery Systems Market

As a core segment of the Medical Device industry, the Stereotactic Surgery Systems market develops in line with broader industry shifts. Over recent years, transitions such as Transition to Minimally Invasive Procedures and Frameless Navigation and Minimally Invasive Expansion have redefined priorities across the Medical Device sector, influencing how the Stereotactic Surgery Systems market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition to Minimally Invasive Procedures

In the United States and in Germany there is an increasing trend towards minimally invasive surgery. It will contribute a total of $682 million towards revenues by the year 2030. With a focus on cutting back on hospital stays, fewer complications and better end results, neurosurgery, stereotactic radiation and image guided surgery are gaining popularity. The shift in focus is directed towards higher end planning software, integrated imaging and robotic surgery systems, which in turn enables the companies with the best Stereotactic Surgery Systems that are optimised for workflow and are interoperable to strengthen their positions in the market. With this, hospitals procurement strategies and investment decisions are being linked to the equipment that allows a reduction in the number of surgeries needing an open incision and expansion of minimally invasive procedures performed.
02

Frameless Navigation and Minimally Invasive Expansion

Another significant transition in the stereotactic surgery systems market is the shift from traditional frame‑based techniques to frameless navigation systems coupled with advanced imaging modalities like MRI and CT. This evolution supports less invasive procedures, greater patient comfort, and broader adoption in ambulatory surgical centers beyond conventional hospital settings. Hospitals increasingly invest in software‑driven stereotactic planning and navigation that enhances procedural accuracy while reducing operative time and recovery duration, driving growth in neurological and oncology applications worldwide.